AZD 1705
Alternative Names: AZD-1705Latest Information Update: 08 Mar 2024
Price :
$50 *
At a glance
- Originator AstraZeneca
- Class Antihyperlipidaemics
- Mechanism of Action ANGPTL3 protein expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Dyslipidaemias
Most Recent Events
- 22 Jan 2024 Preclinical trials in Dyslipidaemias in United Kingdom (SC) before January 2024
- 16 Jan 2024 Phase-I clinical trials in Dyslipidaemias (Treatment-experienced) in USA (SC) (NCT06238466) (7003705070
- 12 Jan 2024 AstraZeneca plans a phase I trial for Dyslipidaemias (Treatment-experienced) in USA (SC, Injection) in January 2024 (NCT06216353)